Alka-372–001: first-in-human, phase I study of entrectinib—an oral pan-trk, ROS1, and ALK inhibitor—in patients with advanced solid tumors with relevant molecular alterations - Braud, F GD; Niger, M; Damian, S (J Clin Oncol, 2015)